Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (41-50 of 432) with videos related to

Pageof 44
Sort By:
Seminars in Hematology|May 16, 2002
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapyHervé Dombret, Pierre Fenaux, Steven L Soignet, et al.
Leukemia Research|August 8, 2006
Predisposition to therapy-related acute leukemia with balanced chromosomal translocations does not result from a major constitutive defect in DNA double-strand break end joiningValérie Coiteux, Rosine Onclercq-Delic, Pierre Fenaux, et al.
International Journal of Molecular Sciences|September 28, 2021
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid LeukemiaThomas Cluzeau, Michael Loschi, Pierre Fenaux, et al.
Haematologica|June 8, 2006
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemiaXavier Thomas, Arnaud Pigneux, Emmanuel Raffoux, et al.
Annals of Hematology|August 10, 2018
Autoimmune manifestations associated with myelodysplastic syndromesEric Grignano, Vincent Jachiet, Pierre Fenaux, et al.
Leukemia Research|October 6, 2009
High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemiaRamzi Jeddi, Hèla Ghédira, Samia Mnif, et al.
Haematologica|June 14, 2005
Mutations of PTPN11 are rare in adult myeloid malignanciesLeroy Hugues, Hélène Cavé, Nathalie Philippe, et al.
British Journal of Haematology|March 22, 2003
Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysisEmmanuelle Bourgeois, Marie T Caulier, Catherine Delarozee, et al.
Leukemia Research|November 25, 2016
Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)Antonio Almeida, Pierre Fenaux, Alan F List, et al.
Journal of Medical Economics|October 13, 2011
A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromesRisha Gidwani, Zeba M Khan, Pierre Fenaux, et al.
Pageof 44

Showing results (41-50 of 432) with videos related to

Sort By:
Pageof 44
Seminars in Hematology|May 16, 2002
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapyHervé Dombret, Pierre Fenaux, Steven L Soignet, et al.
Leukemia Research|August 8, 2006
Predisposition to therapy-related acute leukemia with balanced chromosomal translocations does not result from a major constitutive defect in DNA double-strand break end joiningValérie Coiteux, Rosine Onclercq-Delic, Pierre Fenaux, et al.
International Journal of Molecular Sciences|September 28, 2021
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid LeukemiaThomas Cluzeau, Michael Loschi, Pierre Fenaux, et al.
Haematologica|June 8, 2006
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemiaXavier Thomas, Arnaud Pigneux, Emmanuel Raffoux, et al.
Annals of Hematology|August 10, 2018
Autoimmune manifestations associated with myelodysplastic syndromesEric Grignano, Vincent Jachiet, Pierre Fenaux, et al.
Leukemia Research|October 6, 2009
High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemiaRamzi Jeddi, Hèla Ghédira, Samia Mnif, et al.
Haematologica|June 14, 2005
Mutations of PTPN11 are rare in adult myeloid malignanciesLeroy Hugues, Hélène Cavé, Nathalie Philippe, et al.
British Journal of Haematology|March 22, 2003
Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysisEmmanuelle Bourgeois, Marie T Caulier, Catherine Delarozee, et al.
Leukemia Research|November 25, 2016
Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)Antonio Almeida, Pierre Fenaux, Alan F List, et al.
Journal of Medical Economics|October 13, 2011
A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromesRisha Gidwani, Zeba M Khan, Pierre Fenaux, et al.
Pageof 44